Creo Medical (CREO): Progressing on all fronts

London, UK, 23 January 2023

Creo Medical (CREO): Progressing on all fronts

2022 was an eventful year for Creo Medical, as it progressed on all fronts of its Build, Buy and Partner strategy. The period was marked by the increasing traction of Speedboat Inject (its flagship electrosurgical device) and its proprietary CROMA technology platform. Enhanced levels of user, robotics deals with Intuitive and CMR, and multiple heads of terms agreements all suggest a potential inflection point for Creo. To factor in these developments and the improved visibility of the companys near-term plans, we have revisited our model assumptions and introduced more granularity to our estimates. We now categorise Creos revenue stream from three sources: Core technology, Consumables and Partnerships, resulting in our valuation rising to £493m or 272p/share, from £489m (269p/share) previously. We note that at current burn rates, Creo would need to raise funds by Q223 to continue supporting its development plans.

Our valuation is virtually unchanged at £493m or 272p/share after incorporating changes in our forecasts, including inclusion of ex-Europe consumables sales and the expected contribution from the Intuitive deal, partially offset by a more protracted ramp-up of the Speedboat Inject user base we now assume. We estimate the need to raise a total of £25m before turning EBITDA-positive in H225 and achieving net profitability in H126 (previously £30m and FY25, respectively).

Click here to view the full report or here to sign up to receive research as it is published.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached across institutions, family offices, wealth managers and retail investors Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edisons reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Soo Romanoff +44 (0)20 3077 5700 healthcare@edisongroup.com

Jyoti Prakash +44 (0)20 3077 5700 healthcare@edisongroup.com

Nidhi Singh +44 (0)20 3077 5700 healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        www.linkedin.com/company/edison-group-/

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv